Intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours

Trial Profile

Intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Jan 2013

At a glance

  • Drugs Aflibercept (Primary) ; Fluorouracil; Folinic acid; Irinotecan
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Regeneron Pharmaceuticals; Sanofi
  • Most Recent Events

    • 09 Jan 2013 Status changed from recruiting to completed.
    • 11 Jun 2008 New trial record.
    • 06 Jun 2008 Results were presented at the 44th American Society of Clinical Oncology (ASCO) annual meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top